Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a research report sent to investors on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock.

Other equities analysts have also recently issued reports about the company. Oppenheimer dropped their target price on Cellectis from $11.00 to $10.00 and set an outperform rating for the company in a report on Wednesday, June 12th. JMP Securities reiterated a market outperform rating and issued a $6.00 price objective on shares of Cellectis in a research report on Friday, May 31st.

Cellectis Stock Performance

Shares of CLLS stock opened at $2.18 on Thursday. Cellectis has a 1-year low of $0.96 and a 1-year high of $3.77. The company has a current ratio of 1.92, a quick ratio of 1.92 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $121.40 million, a price-to-earnings ratio of -1.69 and a beta of 3.09. The stock’s fifty day simple moving average is $2.21 and its 200-day simple moving average is $2.41.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.05. The business had revenue of $9.50 million for the quarter, compared to the consensus estimate of $6.00 million. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. On average, sell-side analysts predict that Cellectis will post -0.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellectis

Several hedge funds have recently added to or reduced their stakes in CLLS. XTX Topco Ltd acquired a new position in Cellectis in the second quarter valued at about $29,000. Principal Financial Group Inc. grew its holdings in shares of Cellectis by 2.9% during the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock worth $817,000 after purchasing an additional 12,467 shares during the last quarter. Baillie Gifford & Co. grew its holdings in shares of Cellectis by 1.3% during the first quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock worth $2,192,000 after purchasing an additional 10,605 shares during the last quarter. Finally, Long Focus Capital Management LLC grew its holdings in shares of Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares during the last quarter. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.